Effects of cannabidiol on the signs and comorbidities of autistic spectrum disorder

• Autor(a) principal: Minella, Flávia Cristina Osaku
• Data de Publicação: 2021
• Outros Autores: Linartevichi, Vagner Fagnani
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/18607
• topic: Transtorno do Espectro Autista; Tratamento; Canabidiol; Cannabis.; Autistic Spectrum Disorder; Treatment; Canabidiol; Cannabis.; Trastorno del Espectro Autista; Tratamento; Canabidiol; Cannabis.

Autism is considered a neuropsychiatric disorder, with development in early childhood, with losses in the following domains: social interaction, communication, restricted interests and stereotyped patterns of behavior. There is no established definitive treatment for autism, and the objective of pharmacological ones is the relief of specific signs. In general, traditionally used medications (atypical antipsychotics, selective serotonin reuptake inhibitors, stimulants and anticonvulsants) have several side effects, reflecting treatment discontinuation. Cannabidiol (CBD), a component of the Cannabis Sativa plant, is free from lysergic effects and has been used as an alternative to the treatment of Autistic Spectrum Disorder (ASD). The endocaninoid system acts in several physiological functions, accessing the therapeutic potential of CBD in the regulation of hyper or hypostimulated functions. Thus, a systematic review of clinical studies that used CBD in the treatment of signs and comorbidity of ASD was prepared. The databases used were PubMed and Medline, considering the following descriptors in each database: “autismo” and “treatment” and “cannabis”; and “autismo” and “treatment” and “canabidiol”, in the title and abstract. Manuscripts must be published in national and international journals, in English and Portuguese, and free full text. The selected manuscripts were read in full and relevant data extracted for analysis and interpretation. The results presented that overall, clinical trial participants have been shown to have improvements in all signs associated with the ASD considered in each study.